Cytokinetics Q1 Earnings Call Highlights

Key Points

• MYQORZO U.S. launch generated first product revenue of $4.8 million in Q1 (about nine weeks), with early uptake including >275 prescribers, ~680 patients prescribed by quarter‑end (1,100 through April) and >1,400 REMS‑certified HCPs, while payer access is ~90% of Medicare lives and commercial coverage is advancing.
• The Phase 3 ACACIA‑HCM trial of aficamten in non‑obstructive HCM met both dual primary endpoints (statistically significant improvements in KCCQ and peak VO2) and will prompt regulatory discussions toward a supplemental NDA, although safety signals included recurrence of LVEF <50% in 10% of treated patients versus 1% on placebo and two serious heart‑failure events.
• Financially, Cytokinetics reported total Q1 revenue of $19.4 million (including an $11.9 million milestone), a net loss of $206 million (‑$1.67/share), about $1.1 billion in cash and investments, and maintained 2026 combined GAAP R&D and SG&A guidance of $830–870 million.

Cytokinetics NASDAQ: CYTK highlighted the first full quarter as a commercial-stage company during its first-quarter 2026 earnings call, pointing to early U.S. demand for its newly launched hypertrophic cardiomyopathy (HCM) drug MYQORZO, a recent European approval, and positive top-line results from the Phase 3 ACACIA-HCM trial of aficamten in non-obstructive HCM (nHCM).

MYQORZO U.S. launch delivers first product revenue

President and CEO Robert Blum said the company’s most significant development in the quarter was the U.S. launch of MYQORZO for adults with symptomatic obstructive HCM (oHCM), Cytokinetics’ first approved medicine. Blum said early commercial indicators, including prescriber engagement and the pace of REMS certifications, reinforced the company’s view of a “significant opportunity ahead.”

EVP and Chief Commercial Officer Andrew Callos said MYQORZO became available to patients on January 27, and prescribing began within days. Cytokinetics reported $4.8 million in net product revenue in the first quarter, reflecting about nine weeks of sales. Sung Lee, EVP and CFO, said the net product revenue reflected that “over 70% of dispensed patients” were on a paid prescription, with the remainder receiving drug through free trial, bridge, or patient assistance programs.

Callos described the company’s launch strategy as emphasizing “deepening prescribing” among high-volume prescribers who historically generate the majority of prescriptions in the category. He said Cytokinetics’ field team detailed over 90% of these high-volume writers in the first quarter and plans to maintain that emphasis “until we achieve over 50% new-to-brand prescription share among these HCPs,” which the company anticipates by year-end.

Cytokinetics also shared three launch metrics it plans to report: breadth and depth of prescribing and the volume of unique patients. Callos said that in the first quarter:

• More than 275 unique healthcare providers prescribed MYQORZO (over 50% from high-volume writers).
• By April, more than 425 healthcare providers had prescribed the drug.
• Approximately 680 patients had been prescribed MYQORZO by the end of the quarter, rising to 1,100 through April.
• Cytokinetics’ internal analysis suggested a greater than 30% new-to-brand exit share in Q1, though Callos said data limitations make precise measurement difficult.
• More than 1,400 healthcare providers became REMS certified during the quarter.

Callos also pointed to payer access efforts, stating the company had “comparable access for nearly 90% of Medicare lives” and expected to reach parity in Medicare within the second quarter. For commercial coverage, he said Cytokinetics expects 50% access by early Q3 and parity by the end of Q4.

European approval, Germany launch preparations

Blum said the European Commission approved MYQORZO for patients with oHCM during the quarter and that Cytokinetics was moving toward its first European commercial launch in Germany in the second quarter of 2026. Callos said the company completed hiring and onboarding its full German team and had submitted six health technology assessment (HTA) dossiers across the EU, with five more expected to be submitted in the current quarter.

Callos also noted an MAA submission to Swissmedic, while Blum said Cytokinetics already has a marketing application under review in Canada and that partner Sanofi is progressing potential approvals in Hong Kong and Taiwan.

ACACIA-HCM posts positive Phase 3 results for aficamten in non-obstructive HCM

Management said the company reported positive top-line results from ACACIA-HCM, a pivotal Phase 3 trial evaluating aficamten in nHCM, a condition Blum said currently has “no currently approved therapies.” Blum said the company was “very pleased” to see improvements in symptoms and exercise capacity “with no new safety signals observed,” and said Cytokinetics plans to meet with regulators, including the FDA, to discuss submitting a supplemental NDA.

EVP of R&D Fady Malik provided additional detail, saying the trial met both dual primary endpoints, showing statistically significant improvements from baseline to week 36 in:

• KCCQ clinical summary score: +11.4 points with aficamten vs. +8.4 with placebo (least squares mean difference 3 points; P=0.021).
• Peak VO2: +0.64 mL/kg/min with aficamten vs. -0.03 with placebo (least squares mean difference 0.67 mL/kg/min; P=0.003).

Malik said statistically significant improvements were also observed in key secondary endpoints, including NYHA functional class improvement, a composite Z-score of ventilatory efficiency and peak VO2, and NT-proBNP. On safety, Malik said there were “no new safety signals identified,” but noted differences in left ventricular ejection fraction (LVEF) events between treatment and placebo. Recurrence of LVEF below 50% occurred in 10% of patients on aficamten, including two patients who experienced a serious adverse event of heart failure, compared with 1% on placebo. Treatment interruptions due to LVEF below 40% occurred in 3% of patients taking aficamten.

Malik said Cytokinetics plans to submit ACACIA-HCM results for presentation at an upcoming medical meeting but would not provide additional details beyond the press release until then.

Pipeline updates across HCM and heart failure

Chief Medical Officer Stuart Kupfer said the company continued to advance multiple aficamten studies in HCM. He said partner Bayer continued the Phase 3 CAMELLIA-HCM trial in Japanese patients with obstructive HCM, while Cytokinetics continued enrolling CEDAR-HCM in pediatric obstructive HCM, with expected completion of enrollment in the adolescent cohort by the end of 2026. Kupfer also said the company continued enrollment of the Japanese cohort of ACACIA-HCM.

Kupfer added that aficamten received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for non-obstructive HCM in adults and obstructive HCM in pediatric patients.

In heart failure, Kupfer said COMET-HF, the confirmatory Phase 3 trial of omecamtiv mecarbil in patients with symptomatic heart failure and severely reduced ejection fraction (less than 30%), was “progressing well,” with all U.S. and European sites activated and additional sites being added in China. He said the company plans to continue enrollment through 2026. He also said AMBER-HFpEF, the Phase 2 trial of ulicamten in heart failure with preserved ejection fraction (at least 60%), expanded enrollment in Cohort 1 after a recommendation to collect more data at current doses, with enrollment expected to complete in the second half of 2026.

Financial results and 2026 guidance maintained

Lee reported total first-quarter revenue of $19.4 million, compared with $1.6 million in the same period in 2025. In addition to MYQORZO product revenue, Cytokinetics recorded $2.6 million in collaboration revenue and $11.9 million from achieving a milestone under its Bayer license agreement tied to the first commercial sale of MYQORZO in the U.S.

On expenses, Lee said R&D was $95.5 million versus $98.3 million a year earlier, while SG&A rose to $104.9 million from $57.4 million, driven primarily by launch-related costs and personnel-related expenses. Cytokinetics reported a net loss of $206 million, or $1.67 per share, compared with a net loss of $161.4 million, or $1.36 per share, in the prior-year quarter.

Cytokinetics ended the quarter with approximately $1.1 billion in cash and investments, down from $1.2 billion at the end of 2025, with cash and investments declining by about $144 million during the quarter.

Lee said the company maintained its full-year 2026 guidance for combined GAAP R&D and SG&A expenses of $830 million to $870 million, including expected stock-based compensation of $120 million to $130 million. He said Cytokinetics would provide future updates on any potential impact from the ACACIA-HCM results.

Blum closed by outlining anticipated 2026 milestones, including meeting with regulatory authorities on ACACIA-HCM results and potential supplemental NDA plans, launching MYQORZO in Germany in Q2, a potential FDA decision on the MAPLE-HCM supplemental NDA in Q4 with a PDUFA date of November 14, and completion of enrollment in the adolescent cohort of CEDAR-HCM in Q4.

About Cytokinetics NASDAQ: CYTK

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.